Page 49 - Pharma

Omkar Speciality files patent for hepatitis C drug raw material

The company has filed patent for the key critical intermediate required for producing Hep C drug ledipasvir, which is currently manufactured by companies such as Cipla, Cadila & Ranbaxy

Mindteck to collaborate with MNC medical device maker

The company is engaging in a remote patient monitoring project for a multinational corporation specialising in the design and manufacture of medical devices

Dr Reddy's partners with AstraZeneca to promote diabetes drug saxagliptin

As per the deal, Dr Reddy's will distribute Riax (saxagliptin) and Riax M (a fixed dose combination of saxagliptin with metformin) - both brands owned by AstraZeneca - in India

Max Healthcare acquires Pushpanjali Crosslay Hospital for Rs 287 cr

The hospital, which has the capacity to expand up to 540 beds, is NABH and NABL accredited and has been operational since 2010

Merck Millipore develops compaction technology for biopharma

New technology compacts dry powder cell culture media into granules, accelerating solubility and improving flowability & handling

Amgen joins hand with Roche for clinical research of cancer drugs

The company has agreed to collaborate with Roche for cancer immunotherapy study with investigational medicines - talimogene laherparepvec and atezolizumab

Air Liquide's unit Schulke buys Healthcare Antisepsis from Ethicon

This acquisition is in line with the development strategy for Air Liquide's hygiene business activity and allows the company to develop its business in Asia

US FDA grants approval for Aurobindo Pharma's metronidazole tablets

With this, Aurobindo has a total of 194 ANDA approvals - 167 final approvals including 9 from Aurolife Pharma LLC and 27 tentative approvals - from US FDA

Stempeutics receives EU orphan drug designation for novel stem cell drug

The company has received orphan designation for Stempeucel for the treatment of thromboangiitis obliterans

Government plans to open 1000 more Jan Aushadhi stores

The stores will be renamed, rebranded and will increasingly involve qualified pharmacists

Why companies struggle to implement sustainability programs?

US chemical companies have complained that there is no market for specifically 'green products'. There is a strong disconnect currently between customers and manufacturers

Sun Pharma, AstraZeneca ink distribution pact for heart drug ticagrelor

As per the deal, Sun Pharma will be distribute AstraZeneca's brand Axcer - a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome - in India

German keen to invest in hi-tech manufacturing in India

A study has identified opportunities and challenges in high-technology Indo-German collaboration, especially for dual use technologies where there are export controls

Suven Life receives patent for CNS drug in Mexico and Singapore

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven

CVS Health to buy Omnicare in a $12.7 bn deal

With this acquisition, CVS Health will significantly expand its ability to dispense prescriptions in assisted living and long term care facilities, serving the senior patient population

Glenmark gets tentative US FDA nod for epilepsy drug Rufinamide

Rufinamide tablet, which is a therapeutic equivalent of Banzel tablets of Eisai Inc, is used to treat seizures caused by Lennox-Gastaut syndrome

Jacobs bags contract for Bristol-Myers Squibb's biologics plant

The company will provide architectural and engineering services for the new facility, which will increase Bristol-Myers Squibb's biologics manufacturing capacity

Strides Arcolab acquires Aspen's generics biz in Australia for A$ 380 mn

The company will acquire a generic pharmaceutical business in Australia together with certain branded pharmaceutical assets from South African firm Aspen Pharmacare Holdings

AstraZeneca to set up $285-mn biologics facility in Sweden

The new facility, which will focus on filling and packaging of protein therapeutics, will supply medicines for clinical trial programmes of AstraZeneca and MedImmune

Endo to acquire Par Pharma for $8 bn

The combination will create a specialty pharmaceutical company with one of industry's fastest growing generics businesses